<div id="readability-page-1">10:29 AM EST, 12/01/2025 (MT Newswires) -- Lenz Therapeutics ( LENZ ) and Lotus Pharmaceutical said Monday that Lotus submitted a new drug application to South Korea's Ministry of Food and Drug Safety for Vizz to treat presbyopia in adults.The submission was supported by data from phase 3 trials in the US in which Vizz met all primary and secondary near vision improvement endpoints, the companies said.Under the May 2025 license and commercialization agreement, Lenz Therapeutics ( LENZ ) is eligible to receive up to $125 million in regulatory and commercial milestone payments along with tiered, double-digit royalties on future net sales, according to the companies.Shares of Lenz Therapeutics ( LENZ ) were down over 1% in recent trading.Price: 29.72, Change: -0.80, Percent Change: -2.63 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

LENZ

Lenz Therapeutics 和 Lotus Pharmaceutical 已向韩国食品药品安全部提交了 Vizz 的新药申请，该药物用于治疗老花眼。该申请得到了美国成功的三期临床试验数据的支持。Lenz Therapeutics 可能会获得高达 1.25 亿美元的里程碑付款和版税。Lenz 的股价下跌超过 1%，交易价格为 29.72 美元

LENZ Therapeutics 和 Lotus Pharmaceutical 表示，治疗老花眼的新药申请已在韩国提交